For laboratory and research use only — not for human consumption. All content is educational.
Stack guide

Best nootropic peptide stacks of 2026

A "stack" is a combination of two or more peptides chosen because their mechanisms cover complementary endpoints with minimal redundancy. The four combinations below are the most-replicated in published research, ranked by depth of supporting evidence.

The four stacks worth knowing

Semax + Selank — the cognition-mood pairing

Cognitive + Anxiolytic

The most-replicated multi-peptide protocol in the Russian literature. Semax handles the BDNF/NGF-mediated cognitive endpoint; Selank handles the enkephalin-mediated anxiolytic endpoint. Mechanism overlap is minimal, which is why the stack is effective rather than redundant. Most published protocols stagger administration (Semax morning, Selank as-needed or pre-stressor).

N-Acetyl Semax + N-Acetyl Selank — the extended-release equivalent

Extended-action variant

Same logic as the parent-compound stack but with terminal modifications that extend duration of action. Practically: fewer doses per day for similar pharmacodynamic effect. Analogue-specific long-term safety data is sparser than for the parent compounds — a research-planning consideration.

Cerebrolysin + Semax — the heavy-neurotrophic stack

Neurotrophic

Used in some Russian post-stroke and post-traumatic-brain-injury rehabilitation protocols. Cerebrolysin provides multi-component neurotrophic support; Semax adds focused BDNF/NGF induction and intranasal CNS access. Cerebrolysin's parenteral route limits this to clinical-research contexts.

DSIP + Semax — sleep architecture + cognitive consolidation

Sleep + Cognition

Memory consolidation is downstream of slow-wave sleep. The rationale for stacking a sleep-architecture peptide with a daytime cognitive peptide is that the consolidation step itself is the bottleneck for many learning protocols. DSIP at the evening boundary, Semax through the day.

A note on stacking decisions

Stacking research peptides multiplies the unknowns. Each individual peptide has its own limited human safety data; combinations have correspondingly less. Researchers planning protocols should treat stack data with greater epistemic caution than single-peptide data, particularly where mechanisms overlap (multiple BDNF inducers) or where one component has theoretical safety questions (Dihexa's c-Met activation, for example). All combinations remain strictly research-use; this site does not recommend any peptide stack for human consumption.